MA43551A - Protéines immunomodulatrices à variants du ligand icos et leurs utilisations - Google Patents

Protéines immunomodulatrices à variants du ligand icos et leurs utilisations

Info

Publication number
MA43551A
MA43551A MA043551A MA43551A MA43551A MA 43551 A MA43551 A MA 43551A MA 043551 A MA043551 A MA 043551A MA 43551 A MA43551 A MA 43551A MA 43551 A MA43551 A MA 43551A
Authority
MA
Morocco
Prior art keywords
variant
immunomodulator
proteins
icos
ligand
Prior art date
Application number
MA043551A
Other languages
English (en)
Inventor
Michael Kornacker
Ryan Swanson
Original Assignee
Alpine Immune Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpine Immune Sciences Inc filed Critical Alpine Immune Sciences Inc
Publication of MA43551A publication Critical patent/MA43551A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA043551A 2016-04-15 2017-04-14 Protéines immunomodulatrices à variants du ligand icos et leurs utilisations MA43551A (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662323608P 2016-04-15 2016-04-15
US201662394745P 2016-09-14 2016-09-14
US201662410842P 2016-10-20 2016-10-20
US201762472568P 2017-03-16 2017-03-16
US201762475162P 2017-03-22 2017-03-22

Publications (1)

Publication Number Publication Date
MA43551A true MA43551A (fr) 2018-11-07

Family

ID=60042799

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043551A MA43551A (fr) 2016-04-15 2017-04-14 Protéines immunomodulatrices à variants du ligand icos et leurs utilisations

Country Status (13)

Country Link
US (3) US10882914B2 (fr)
EP (1) EP3442999A2 (fr)
JP (3) JP7058609B2 (fr)
KR (4) KR20230051602A (fr)
CN (1) CN110088126A (fr)
AU (1) AU2017250358B2 (fr)
CA (1) CA3019199A1 (fr)
IL (3) IL313289A (fr)
MA (1) MA43551A (fr)
MX (2) MX2018012472A (fr)
NZ (3) NZ787246A (fr)
SG (1) SG11201808457PA (fr)
WO (1) WO2017181148A2 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2877589B1 (fr) 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoprotéines ayant des propriétés anti-inflammatoires
SG11201706583PA (en) 2015-02-19 2017-09-28 Compugen Ltd Anti-pvrig antibodies and methods of use
RS61943B1 (sr) 2015-04-17 2021-07-30 Alpine Immune Sciences Inc Imunomodulatorni proteini sa prilagodljivim afinitetima
JP6936221B2 (ja) 2015-11-02 2021-09-15 ファイブ プライム セラピューティクス， インコーポレイテッド Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用
MX2018012472A (es) * 2016-04-15 2019-08-12 Alpine Immune Sciences Inc Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
IL310729A (en) 2016-04-15 2024-04-01 Alpine Immune Sciences Inc Immunomodulatory proteins that are variants of CD80 and their uses
EP3491013A1 (fr) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Protéines immunomodulatrices à variants de cd155 et leurs utilisations
WO2018022945A1 (fr) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Protéines immunomodulatrices à variants de cd112 et utilisations associées
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
SG11201901077RA (en) 2016-08-17 2019-03-28 Compugen Ltd Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
EP3529265A2 (fr) * 2016-10-19 2019-08-28 Cellectis Cellules allogéniques modifiées par une nucléase d'effecteur tal (talen) appropriées pour une thérapie
AU2017345764A1 (en) * 2016-10-20 2019-05-02 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
JP2020511144A (ja) 2017-03-16 2020-04-16 アルパイン イミューン サイエンシズ インコーポレイテッド Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用
EP3596114A2 (fr) 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Protéines immunomodulatrices à variants de cd80 et leurs utilisations
AU2018258661A1 (en) 2017-04-28 2019-10-17 Five Prime Therapeutics, Inc. Methods of treatment with CD80 extracellular domain polypeptides
EP3634466A4 (fr) * 2017-06-06 2021-03-24 Relinia, Inc. Protéines de fusion agonistes du récepteur 2 du tnf monocaténaire
WO2019074983A1 (fr) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Protéines immunomodulatrices de variants de ctla-4 et leurs utilisations
JP7282760B2 (ja) * 2017-10-18 2023-05-29 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
WO2019136179A1 (fr) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Protéines immunomodulatrices multi-domaine et leurs méthodes d'utilisation
JP2021519289A (ja) 2018-03-27 2021-08-10 システィミューン， インク．Ｓｙｓｔｉｍｍｕｎｅ， Ｉｎｃ． ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法
WO2019226922A1 (fr) * 2018-05-24 2019-11-28 Rush University Medical Center Icosl destiné à être utilisé comme agent thérapeutique rénal
US12065476B2 (en) 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof
BR112021003156A2 (pt) 2018-08-23 2021-05-11 Seagen, Inc. composição, anticorpo que se liga ao tigit humano, formulação farmacêutica, polinucleotídeo isolado, vetor, célula hospedeira, métodos para a produção de um anticorpo que se liga ao tigit humano e de anticorpos afucosilados que se ligam a tigit e para o tratamento de um câncer, e, kit.
JP7713886B2 (ja) 2018-11-30 2025-07-28 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｄ８６バリアント免疫調節タンパク質およびその使用
JP7683932B2 (ja) * 2019-01-24 2025-05-27 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド ナチュラルキラー細胞を刺激するための組成物及び方法
TW202045544A (zh) 2019-02-22 2020-12-16 美商戊瑞治療有限公司 用於治療ＰＤ－Ｌ１陰性腫瘤之ＣＤ８０胞外結構域Ｆｃ融合蛋白
JP7810554B2 (ja) * 2019-03-01 2026-02-03 アケロイス バイオファーマ， インコーポレイテッド 抗原特異的免疫細胞におけるｃｄ１６０機能をモジュレートする方法およびその使用
CN113543792A (zh) * 2019-03-08 2021-10-22 奥托路斯有限公司 包含工程化嵌合抗原受体和car调节剂的组合物和方法
KR20220035032A (ko) * 2019-04-17 2022-03-21 알파인 이뮨 사이언시즈, 인코포레이티드 변이체 icos 리간드(icosl) 융합 단백질의 방법 및 용도
EP3999079A4 (fr) * 2019-07-19 2024-04-03 Memorial Sloan Kettering Cancer Center Polypeptide de fusion pour l'immunothérapie
AU2021226352A1 (en) * 2020-02-25 2022-09-29 Momenta Pharmaceuticals, Inc. Enzymes for sialylation of glycans
WO2021226551A1 (fr) 2020-05-08 2021-11-11 Alpine Immune Sciences, Inc. Protéines immunomodulatrices inhibitrices d'april et de baff et leurs procédés d'utilisation
EP4469069A4 (fr) * 2022-01-28 2026-05-06 Univ North Carolina Chapel Hill Lymphocytes t tueurs naturels et leurs procédés d'utilisation
EP4486787A4 (fr) * 2022-03-03 2026-02-11 Univ Texas Récepteurs antigéniques chimériques anti-cd19 et anti-cd79b et leurs procédés d'utilisation
US20250326816A1 (en) * 2022-05-03 2025-10-23 Korea University Research And Business Foundation Icos-l variant with enhanced binding affinity for icos
WO2025072726A1 (fr) 2023-09-29 2025-04-03 Trex Bio, Inc. Molécules de fusion de variant de tnf-alpha

Family Cites Families (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (fr) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Anticorps alteres
US5443964A (en) 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
US6218525B1 (en) 1988-02-25 2001-04-17 The General Hospital Corporation Nucleic acid encoding CD28
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6641809B1 (en) 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
CA2102623C (fr) 1991-05-06 2003-04-22 Jeffrey Schlom Virus recombinant exprimant un antigene carcino-embryonnaire et methodes d'utilisation
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US6130316A (en) 1993-07-26 2000-10-10 Dana Farber Cancer Institute Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
US6218510B1 (en) 1994-03-02 2001-04-17 Brigham & Woman's Hospital B7-1 and B7-2 polypeptides
US20020159979A1 (en) 1994-06-06 2002-10-31 Children's Hospital, Inc. Adeno-associated virus materials and methods
US6361770B1 (en) 1994-09-23 2002-03-26 University Of British Columbia Method of enhancing expression of MHC class I molecules bearing endogenous peptides
WO1996010419A2 (fr) 1994-10-03 1996-04-11 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services, Office Of Technology Transfer Composition comprenant un virus de recombinaison exprimant un antigene et un virus de recombinaison exprimant une molecule immunostimulatrice
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
US5767071A (en) 1995-06-07 1998-06-16 Ixsys Incorporated Sevenmer cyclic peptide inhibitors of diseases involving αv β3
US5780426A (en) 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
FR2735789B1 (fr) 1995-06-23 1997-07-25 Centre Nat Rech Scient Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
EP1983057A3 (fr) 1995-09-08 2009-01-07 Genzyme Corporation Vecteurs AAV améliorés pour la thérapie génique
US7001765B2 (en) 1996-03-06 2006-02-21 Medigene Ag Adeno-associated virus vector for boosting immunogenicity of cells
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US6730512B2 (en) 1997-04-09 2004-05-04 Amdl, Inc. Combination immunogene therapy
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
AU8828598A (en) 1997-08-15 1999-03-08 Rubicon Laboratory, Inc. Retrovirus and viral vectors
JP2001517454A (ja) 1997-09-19 2001-10-09 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスの産生に有用な方法および細胞株
GB9801930D0 (en) 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
US6436392B1 (en) 1998-05-20 2002-08-20 University Of Iowa Research Foundation Adeno-associated virus vectors
US20040063094A1 (en) 1998-05-20 2004-04-01 Biovex Limited Mutant herpes simplex viruses and uses thereof
GB2337755B (en) 1998-05-29 2003-10-29 Secr Defence Virus vaccine
IL141044A0 (en) 1998-08-07 2002-02-10 Univ Washington Innunological herpes simplex virus antigens and methods for use thereof
ATE454445T1 (de) 1998-11-10 2010-01-15 Univ North Carolina Virusvektoren und verfahren für ihre herstellung und verabreichung.
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
GB9904582D0 (en) 1999-02-26 1999-04-21 Nycomed Imaging As Process
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
DE19933288A1 (de) 1999-07-15 2001-01-18 Medigene Ag Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
US6365619B1 (en) 1999-07-22 2002-04-02 Novartis Ag Treatment of arteriosclerosis
EP2369002A1 (fr) 1999-08-09 2011-09-28 Targeted Genetics Corporation Améliorations de l'expression d'une séquence de nucléotides hétérologues à brin unique à partir de vecteurs viraux recombinants par la désignation de la séquence de manière à ce qu'elle forme des paires de bases intrabrins
PT1218504E (pt) 1999-09-21 2007-10-22 Genetics Inst Llc Novas moléculas gl50 e suas utilizações
US7241447B1 (en) 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
US7329728B1 (en) 1999-10-25 2008-02-12 The Scripps Research Institute Ligand activated transcriptional regulator proteins
WO2001045737A2 (fr) 1999-12-22 2001-06-28 Onyx Pharmaceuticals, Inc. Mutants de glycoproteine c du virus herpes simplex 1 destines au traitement de la croissance de cellules hyperproliferatives non desirees
ATE312189T1 (de) 2000-01-21 2005-12-15 Biovex Ltd Virusstämme für die onkolytische behandlung von krebs
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
AU2001272978A1 (en) 2000-06-23 2002-01-08 Maxygen, Inc. Novel co-stimulatory molecules
US7183376B2 (en) 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules
EP1320599A2 (fr) 2000-06-28 2003-06-25 Genetics Institute, LLC Molecules pd-l2: nouveaux ligands pour pd-1 et leurs utilisations
US7011972B2 (en) 2000-07-18 2006-03-14 The Scripps Research Institute Fusion polypeptide comprising two ligand binding domains
US6635750B1 (en) 2000-07-20 2003-10-21 Millennium Pharmaceuticals, Inc. B7-H2 nucleic acids, members of the B7 family
US6653103B2 (en) 2001-03-30 2003-11-25 Wisconsin Alumni Research Foundation Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides
IL157504A0 (en) 2001-05-11 2004-03-28 Wellstat Biologics Corp Oncolytic virus therapy
JP4572276B2 (ja) 2001-06-29 2010-11-04 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ Ｔ細胞調節遺伝子およびその使用方法
CA2452517A1 (fr) 2001-07-11 2003-01-23 University Of Miami Vsv recombinant pour le traitement de cellules tumorales
CN1304559C (zh) 2001-10-09 2007-03-14 杭州康科生物技术有限公司 表达热休克蛋白的溶瘤微生物及其应用
EP1461073B1 (fr) 2001-11-30 2010-01-06 The Government of the United States of America, as represented by the Secretary Department of Health and Human Services Peptides agonistes d'antigenes specifiques de la prostate et leurs utilisations
US7235631B2 (en) * 2002-02-07 2007-06-26 Mayo Foundation For Medical Education And Research ICOS mutants
JP2005521398A (ja) 2002-03-27 2005-07-21 ベイラー　カレッジ　オブ　メディスン 癌治療用の強力な腫瘍溶解性単純ヘルペスウイルス
US8535672B2 (en) 2002-04-04 2013-09-17 Yissum Research Development Of The Hebrew University Of Jerusalem Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between CD28 and the superantigen and uses thereof
US20030225260A1 (en) 2002-04-30 2003-12-04 Snyder Richard O. Production of recombinant AAV virions
EP1539230A4 (fr) 2002-06-21 2007-10-31 Wellstat Biologics Corp Administration de virus therapeutiques
EP1391213A1 (fr) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions et méthodes pour le traitement du cancer en utilisant un conjugué d'un anticorps contre le CD44 avec un maytansinoide et des agents chimiothérapeutiques
JP2005537802A (ja) 2002-09-09 2005-12-15 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション ラブドウイルスの組み換え型変異体及びその使用方法
US7223408B2 (en) 2002-10-03 2007-05-29 Wyeth Holdings Corporation Human papillomavirus polypeptides and immunogenic compositions
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1944320A1 (fr) 2002-12-16 2008-07-16 Genentech, Inc. Variantes de l'immunoglobuline et leurs utilisations
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
AU2004223808B2 (en) 2003-03-27 2009-03-26 Ottawa Health Research Institute Mutant vesicular stomatitis viruses and use thereof
WO2005047458A2 (fr) 2003-06-18 2005-05-26 Genelux Corporation Micro-organismes therapeutiques
HUE054805T2 (hu) 2003-09-30 2021-09-28 Univ Pennsylvania Adeno-asszociált vírus (AAV) kládok, szekvenciák, az azokat tartalmazó vektorok és alkalmazásaik
JP2007511216A (ja) 2003-11-17 2007-05-10 クルセイド ラボラトリーズ リミテッド 変異ウイルス
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
AU2004309347B2 (en) 2003-12-19 2010-03-04 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
WO2005116224A2 (fr) 2004-05-18 2005-12-08 Children's Memorial Hospital Vecteurs viraux adeno-associes regules par la tetracycline pour l'administration de gene au systeme nerveux
US7427396B2 (en) 2004-06-03 2008-09-23 Genzyme Corporation AAV vectors for gene delivery to the lung
US7731952B2 (en) 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
EP3342782B1 (fr) 2004-07-15 2022-08-17 Xencor, Inc. Variantes optimisées de fc
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
CA2580981C (fr) 2004-09-22 2013-10-22 Kirin Beer Kabushiki Kaisha Anticorps igg4 humains stabilises
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
EP1819823A2 (fr) 2004-12-01 2007-08-22 Bayer Schering Pharma Aktiengesellschaft Generation de virus capables de replication a usage therapeutique
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
CA2611056C (fr) 2005-06-01 2016-06-28 California Institute Of Technology Procede permettant le transfert cible de genes au moyen de vecteurs viraux
JP5284780B2 (ja) 2005-06-23 2013-09-11 ザ ユニバーシティ オブ ヒューストン 癌の治療のための単純ヘルペスウイルス２型変異体の使用
DK1915398T3 (en) 2005-07-18 2016-07-04 Amgen Inc Humane anti-B7RP1 neutraliserende antistoffer
US7943374B2 (en) 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
GB0522476D0 (en) 2005-11-03 2005-12-14 Biovex Ltd Oncolytic herpes virus vectors
BRPI0714495B8 (pt) 2006-07-21 2021-05-25 California Inst Of Techn lentivírus deficiente para replicação recombinante pseudotipado
WO2008100292A2 (fr) 2006-10-16 2008-08-21 Genelux Corporation Souches du virus de la vaccine modifié pour une utilisation dans des procédés diagnostiques et thérapeutiques
AU2007331672A1 (en) 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
WO2008140621A2 (fr) 2006-12-21 2008-11-20 Mount Sinai School Of Medicine Of New York University Virus oncolytiques transgéniques et leurs utilisations
WO2008092117A2 (fr) 2007-01-25 2008-07-31 Xencor, Inc. Nouvelles insertions, délétions et substitutions d'immunoglobulines
US8163292B2 (en) 2007-02-16 2012-04-24 Virttu Biologics Limited Herpes simplex viruses and methods of viral replication
WO2008156655A2 (fr) 2007-06-15 2008-12-24 Genelux Corporation Microorganismes pour une imagerie et/ou un traitement de tumeurs
AU2008293885A1 (en) 2007-07-13 2009-03-05 The John Hopkins University B7-DC variants
EP2173368A1 (fr) 2007-07-18 2010-04-14 Genelux Corporation Utilisation d'un agent chimiothérapeutique dans la préparation d'un médicament pour traiter ou améliorer un effet secondaire indésirable associé à une thérapie virale oncolytique.
EP3415529B1 (fr) 2007-09-26 2020-11-04 Chugai Seiyaku Kabushiki Kaisha Région constante d'anticorps modifié
WO2009054996A2 (fr) 2007-10-25 2009-04-30 Genelux Corporation Systèmes et procédés pour une virothérapie
AU2008329518A1 (en) 2007-11-27 2009-06-04 Viventia Biotechnologies Inc. Antibodies against a cancer-associated epitope of variant NFKBIB and uses thereof
TR201802323T4 (tr) 2007-12-11 2018-03-21 Univ North Carolina Chapel Hill Polipürin yolu modifiye edilmiş retroviral vektörler.
US11260133B2 (en) 2008-02-21 2022-03-01 Sanford-Burnham Medical Research Institute Methods and compositions related to peptides and proteins with C-terminal elements
US8313896B2 (en) 2008-04-04 2012-11-20 The General Hospital Corporation Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
EP2300023A2 (fr) 2008-05-16 2011-03-30 Genelux Corporation Microorganismes pour la prévention et le traitement de néoplasmes accompagnant une thérapie cellulaire
EP2307033A4 (fr) 2008-05-29 2012-06-13 Gen Hospital Corp Utilisation de virus herpes oncolytiques pour tuer des cellules souches cancéreuses
JP2012500652A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド 標的化共刺激ポリペプチドおよび癌を処置するための使用方法
EP3936122A1 (fr) 2008-11-24 2022-01-12 Massachusetts Institute Of Technology Procédés et compositions pour l'administration localisée d'un agent
WO2010080909A1 (fr) 2009-01-08 2010-07-15 Yale University Compositions et procédés d'utilisation de virus de la stomatite vésiculaire à action oncolytique
EP2283810A1 (fr) 2009-07-16 2011-02-16 University College Cork-National University of Ireland, Cork Bactéries à administration orale en tant que véhicules pour l'administration systémique d'agents
US20150359909A1 (en) 2009-07-16 2015-12-17 University College Cork-National University Of Ireland, Cork Orally administered bacteria as vehicles for systemic delivery of agents
KR101790187B1 (ko) 2009-07-24 2017-10-25 이뮨 디자인 코포레이션 신드비스 바이러스 외피 당단백질로 가성형태화된 렌티바이러스 벡터
AU2010282340B2 (en) 2009-08-13 2016-12-22 The Johns Hopkins University Methods of modulating immune function
CN104826106B (zh) 2009-09-30 2019-01-11 斯隆凯特林防癌纪念中心 用于治疗癌症的组合免疫疗法
EP2531216B1 (fr) 2010-02-04 2019-03-27 The Trustees Of The University Of Pennsylvania Icos régule de façon critique l'expansion et la fonction des cellules inflammatoires humaines th17
EP2545073B1 (fr) 2010-03-12 2015-09-30 AbbVie Biotherapeutics Inc. Protéines ctla4 et leurs utilisations
CA2796633C (fr) 2010-04-23 2020-10-27 Genentech, Inc. Production de proteines heteromultimeres
CN103261217B (zh) 2010-11-11 2017-04-26 港大科桥有限公司 可溶性 pd‑1变体、融合构建体及其用途
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
MX348071B (es) 2011-03-16 2017-05-26 Amgen Inc Variantes de fc.
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US9409987B2 (en) 2011-04-15 2016-08-09 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
WO2012149364A1 (fr) 2011-04-28 2012-11-01 Diamond Don J Vaccins associés aux tumeurs et compositions pour l'interruption de l'immunosuppression dérivée de tumeurs destinées à être utilisées en combinaison avec une immunothérapie contre le cancer
TWI496886B (zh) 2011-06-24 2015-08-21 Taipei Veteran General Hospital 提升感染性與惡性疾病之治療之免疫反應
WO2013001517A1 (fr) * 2011-06-30 2013-01-03 Compugen Ltd. Polypeptides et leurs utilisations pour traiter les troubles auto-immuns et l'infection
PT2726101T (pt) 2011-06-30 2018-11-21 Genzyme Corp Inibidores da ativação de células t
US8956619B2 (en) 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
CA2865578C (fr) 2012-02-27 2023-01-17 Amunix Operating Inc. Compositions de conjugues xten et leurs procedes de preparation
DK2831095T3 (en) 2012-03-30 2019-02-18 Immune Design Corp LENTIVIRAL VECTOR PARTICLES WITH IMPROVED TRANSDUCTION EFFICIENCY FOR CELL EXPRESSING DC SIGN
WO2013156054A1 (fr) 2012-04-16 2013-10-24 Universität Stuttgart Domaine 2 de chaîne lourde d'igm et d'ige en tant que modules d'homodimérisation à liaison covalente pour la génération de protéines de fusion à double spécificité
ES2777778T3 (es) 2012-05-11 2020-08-06 Medimmune Ltd Variantes de CTLA-4
EP2925350B1 (fr) * 2012-12-03 2019-01-30 Bristol-Myers Squibb Company Amélioration de l'activité anticancéreuse de protéines de fusion de fc immuno-modulatrices
AU2013355379B2 (en) 2012-12-04 2018-08-09 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
JP2016515120A (ja) 2013-03-15 2016-05-26 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗アルファｖベータ５抗体を用いた急性腎損傷の治療及び予防
EP3683312B1 (fr) 2013-04-23 2022-09-07 Elasmogen Limited Bibliothèque synthétique de molécules de liaison spécifiques
WO2014198002A1 (fr) 2013-06-14 2014-12-18 Ottawa Hospital Research Institute Bactérie produisant une protéine se liant à l'interféron et ses utilisations
US20160271218A1 (en) 2013-06-27 2016-09-22 Mor Research Applications Ltd. Soluble ctla-4 molecules and derivatives thereof for treatment of minimal change disease
GB201311475D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Polypeptides
WO2015103438A2 (fr) 2014-01-02 2015-07-09 Genelux Corporation Traitement d'appoint par un virus oncolytique avec des agents qui augmentent l'infectivité du virus
EP3835318B1 (fr) 2014-01-15 2025-10-29 F. Hoffmann-La Roche AG Variants de région fc à fcrn modifié et propriétés de ligand a protéique maintenues
ES2792849T3 (es) 2014-02-10 2020-11-12 Univ Emory Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer
JP6775422B2 (ja) 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
KR20170032373A (ko) 2014-07-15 2017-03-22 이뮨 디자인 코포레이션 Tlr4 작용제 보조제 및 렌티바이러스 벡터를 이용한 프라임-부스트 요법
EP3552615B8 (fr) 2014-07-16 2022-03-02 Transgene Virus oncolytique pour l'expression de modulateurs de point de contrôle immunitaire
PL3177640T3 (pl) 2014-08-08 2020-11-02 The Board Of Trustees Of The Leland Stanford Junior University Charakteryzujące się wysokim powinowactwem środki terapeutyczne naśladujące PD-11 i sposoby ich wykorzystania
CA2959105C (fr) 2014-09-03 2023-10-17 Bavarian Nordic A/S Virus contre les filovirus a base du virus de la vaccine ankara modifie recombinant (mva)
US20160145344A1 (en) 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
CN107207597A (zh) 2014-11-06 2017-09-26 儿研所儿童医学中心 用于癌症和自身免疫疾病的免疫疗法
EP3020816A1 (fr) 2014-11-11 2016-05-18 University College Cork Thérapie génique à médiation bactérienne
WO2016118577A1 (fr) 2015-01-22 2016-07-28 Medimmune, Llc Protéines de fusion thymosine-bêta-4
US10953045B2 (en) 2015-04-02 2021-03-23 Cancure Limited Agents and compositions for eliciting an immune response
WO2016164428A1 (fr) 2015-04-06 2016-10-13 The Board Of Trustees Of The Leland Stanford Junior University Antagonistes de la voie de signalisation de mort cellulaire programmée 1 (pd-1) basés sur des récepteurs
RS61943B1 (sr) 2015-04-17 2021-07-30 Alpine Immune Sciences Inc Imunomodulatorni proteini sa prilagodljivim afinitetima
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
AU2016298227B9 (en) 2015-07-30 2019-10-31 Macrogenics, Inc. PD-1-binding molecules and methods of use thereof
WO2017023779A1 (fr) 2015-07-31 2017-02-09 Tarveda Therapeutics, Inc. Compositions et méthodes pour thérapies immuno-oncologiques
AU2016303485A1 (en) 2015-07-31 2018-03-01 Tarveda Therapeutics, Inc. Compositions and methods for immunomodulation
EA201890729A1 (ru) * 2015-09-14 2018-09-28 Элпайн Имьюн Сайнс, Инк. Настраиваемые варианты доменов суперсемейства иммуноглобулинов и терапия сконструированными клетками
AU2016333517B2 (en) 2015-10-02 2023-09-07 Les Laboratoires Servier Anti-PD-1 antibodies and compositions
JP7148399B2 (ja) 2015-11-04 2022-10-05 タイペイ・ベテランズ・ジェネラル・ホスピタル 悪性疾患に対する併用療法
JP6955507B2 (ja) 2015-12-14 2021-10-27 マクロジェニクス，インコーポレーテッド Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
MX2018012472A (es) * 2016-04-15 2019-08-12 Alpine Immune Sciences Inc Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
IL310729A (en) 2016-04-15 2024-04-01 Alpine Immune Sciences Inc Immunomodulatory proteins that are variants of CD80 and their uses
AU2017266905B2 (en) 2016-05-18 2022-12-15 Albert Einstein College Of Medicine, Inc. Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
WO2018022945A1 (fr) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Protéines immunomodulatrices à variants de cd112 et utilisations associées
EP3491013A1 (fr) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Protéines immunomodulatrices à variants de cd155 et leurs utilisations
AU2017345764A1 (en) 2016-10-20 2019-05-02 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
IL320149A (en) 2017-03-16 2025-06-01 Alpine Immune Sciences Inc Pd-l1 variant immunomodulatory proteins and uses thereof
JP7282760B2 (ja) 2017-10-18 2023-05-29 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
WO2019136179A1 (fr) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Protéines immunomodulatrices multi-domaine et leurs méthodes d'utilisation
US12065476B2 (en) 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof
KR20220035032A (ko) 2019-04-17 2022-03-21 알파인 이뮨 사이언시즈, 인코포레이티드 변이체 icos 리간드(icosl) 융합 단백질의 방법 및 용도

Also Published As

Publication number Publication date
BR112018070934A2 (pt) 2019-02-26
EP3442999A2 (fr) 2019-02-20
IL262365B1 (en) 2024-07-01
JP2022064959A (ja) 2022-04-26
NZ787246A (en) 2025-12-19
NZ787243A (en) 2025-12-19
IL325681A (en) 2026-02-01
CN110088126A (zh) 2019-08-02
MX2022009923A (es) 2022-09-09
JP7058609B2 (ja) 2022-04-22
KR102824067B1 (ko) 2025-06-23
MX2018012472A (es) 2019-08-12
IL262365B2 (en) 2024-11-01
JP2024138024A (ja) 2024-10-07
KR20250095754A (ko) 2025-06-26
US20210188995A1 (en) 2021-06-24
AU2017250358B2 (en) 2023-06-01
WO2017181148A2 (fr) 2017-10-19
SG11201808457PA (en) 2018-10-30
JP7623967B2 (ja) 2025-01-29
CA3019199A1 (fr) 2017-10-19
AU2017250358A1 (en) 2018-10-18
KR20190005879A (ko) 2019-01-16
US10882914B2 (en) 2021-01-05
KR20230051601A (ko) 2023-04-18
JP2019514361A (ja) 2019-06-06
US20240409660A1 (en) 2024-12-12
NZ746741A (en) 2023-12-22
AU2023202718A1 (en) 2023-05-18
IL313289A (en) 2024-08-01
US20170320959A1 (en) 2017-11-09
KR102536850B1 (ko) 2023-05-26
WO2017181148A3 (fr) 2018-02-01
IL262365A (en) 2018-11-29
US12110339B2 (en) 2024-10-08
KR20230051602A (ko) 2023-04-18
NZ787244A (en) 2025-12-19

Similar Documents

Publication Publication Date Title
MA43552A (fr) Protéines immunomodulatrices à variants de cd80 et leurs utilisations
IL262365A (en) Icos ligand variant immunomodulatory proteins and uses thereof
EP3523328A4 (fr) Protéines actriib à variant et leurs utilisations
EP3810182A4 (fr) Néoantigènes et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
EP3344275A4 (fr) Macrocycles peptidomimétiques et leurs utilisations
EP3504243A4 (fr) Anticorps anti-tim-3 et leurs utilisations
EP3471727A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
MA41460A (fr) Agents de liaison à la tnfrsf et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
EP3472129A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
EP3426288A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3328895A4 (fr) Anticorps anti-pd-l1 et leurs utilisations
EP3294318A4 (fr) Macrocycles peptidomimétiques et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
EP3334706A4 (fr) Pillararènes et utilisations de ceux-ci
EP2991665A4 (fr) Polypeptides à agrafes et à suture et leurs utilisations
EP3283516A4 (fr) Anticorps anti-pacap et leurs utilisations
MA50404A (fr) Protéines immunomodulatrices à variants de ligand de icos variant, compositions et méthodes associées
DK3535397T3 (da) Alfa-v-beta-6-integrin-ligander og anvendelser deraf
EP3478516A4 (fr) Structures multicouches et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
EP3325010A4 (fr) Anticorps anti-facteur de coagulation xia et leurs utilisations
EP3538261A4 (fr) Catalyseurs en pérovskite et leurs utilisations